References
- Present CA, Denes AE, Liu C, et al. Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma: a comparative trial with 6-thioguanine. Cancer, 1984; 53: 2610–2614.
- Engstrom PF, Maclntyre JM, Mittelman A, et al. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin: a phase III trial by the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1984: 7: 313–318.
- Buroker TR, Moertel CG, Fleming TR, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol, 1985; 3: 1624–1631.
- Douglas KT. The thymidylate synthesis cycle and anticancer drugs. Med Res Rev, 1987; 7: 441–475.
- Danenberg P.V. The role of reduced folates in the enhanced binding of FdUMP to dTMP synthetase. In: Bruckner H.W., Rustum Y.M. (Eds.): Advances in cancer chemotherapy: the current status of 5-fluorouracil-leucovorin calcium combination. New York: Park Row Publishers, 1984: 5–11.
- O’Dwyer PJ (Ed.) Development of folates and folic acid antagonists in cancer chemotherapy. NCI Monogr, 1987; 5.
- Erlichman C (Ed.) Leucovorin: an expanding role in chemotherapy. Montreal: Pharmalibri Publ., 1988.